Testing a new drug HLX42 for advanced solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or metastatic solid tumors (including NSCLC) that have not responded to or cannot tolerate standard treatments, or no standard treatment exists.
- You have at least one tumor that can be measured with scans.
- You are able to take care of yourself (ECOG score 0-1) and expected to live more than 3 months.
- You do not have serious lung disease (interstitial lung disease) or other uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests HLX51, a new anti-cancer medicine, to see if it is safe and tolerable in people with advanced solid tumors or lymphoma. It also studies how the body absorbs and processes the drug, and it may help if standard treatments didn’t work or aren’t possible.
Hear when a new Solid Tumor and NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.